United Therapeutics Corporation UTHR

Company Overview

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The company operates within the biopharmaceutical and regenerative medicine industries and generates the majority of its revenue from proprietary PAH therapies marketed globally. Its core products include prostacyclin pathway therapies and vasodilators designed to improve survival and quality of life for patients with rare and chronic conditions.

Founded in 1996, the company was established to commercialize treatments for PAH and has since expanded its scope to include organ manufacturing technologies aimed at addressing the shortage of transplantable organs. United Therapeutics is known for its vertically integrated model that combines drug development, device innovation, and biologics manufacturing. A distinguishing strategic feature is its long-term investment in xenotransplantation and bioengineered organ platforms, positioning the company beyond traditional biopharmaceutical competitors.